Press releases
GSK supports recovery efforts to help those affected by the Japan earthquake
In response to events in Japan as a result of the Tohoku Kanto Earthquake and tsunami that devastated Japan’s north east coastline region, GlaxoSmithKline (GSK) is supporting the ongoing relief efforts by working with the Japanese authorities, the Japan Pharmaceutical Manufacturers Association and local NGOs to assist medical support and pharmaceutical donation needs.
GSK announces positive topline results of Phase lll study of IPX066 in advanced Parkinson’s disease
GlaxoSmithKline (GSK) today announced positive, top-line results of the ADVANCE-Parkinson’s Disease (PD) Phase III clinical study, conducted by Impax Pharmaceuticals, of IPX066 versus immediate-release (IR) carbidopa-levodopa (CD-LD) in advanced PD patients experiencing motor fluctuations. IPX066 is an investigational extended release (ER) CD-LD product which is being developed by Impax in collaboration with GSK. Under the terms of a development and commercialisation agreement, Impax will develop and commercialise IPX066 in the United States and Taiwan, and GSK will develop and commercialise IPX066 in all other markets throughout the world.
GlaxoSmithKline and Tolerx announce phase III DEFEND-1 study of otelixizumab in type 1 diabetes did not meet its primary endpoint
GlaxoSmithKline (GSK) and Tolerx, Inc. today announced that the Phase III DEFEND-1 study of otelixizumab, an investigational humanised anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.
GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta® (belimumab) for the treatment of systemic lupus erythematosus
GlaxoSmithKline plc (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that the U.S. Food and Drug Administration (FDA) has approved Benlysta® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board
GlaxoSmithKline plc (GSK) announces that Ms. Judy Lewent and Ms. Stacey Cartwright have been appointed as Non-Executive Directors and will join the Board of the Company with effect from 1st April 2011.
GSK outlines new plan to drive recruitment and attract graduate talent in the UK
GlaxoSmithKline (GSK) today outlined new plans to encourage talented students graduating from UK universities to consider pursuing a career within the company. These measures are part of the company’s ongoing efforts, as one of the leading FTSE companies and employers in the UK, to ensure the ongoing success of the business.
Regulatory update: Nimenrix® (MenACWY vaccine)
GlaxoSmithKline (GSK) announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for its candidate conjugate meningitis vaccine, Nimenrix®, for active immunisation against invasive meningococcal diseases caused by Neisseria meningitidis serogroups A, C, W-135 and Y.
World’s first everyday fluoride toothpaste with NovaMin® technology that can repair sensitive teeth
GlaxoSmithKline Consumer Healthcare, the maker of leading sensitive toothpaste brand Sensodyne®, today announced a breakthrough in dental care with the launch of new Sensodyne Repair & Protect. The breakthrough formulation, which the company will launch in over 50 European and International markets during 2011, is the first everyday fluoride toothpaste to contain patented NovaMin® technology, which is scientifically proven to repair* sensitive teeth by forming a tooth-like layer over exposed dentine to help continually repair and protect sensitive areas.
Reward for charities bridging gaps in health care provision
Ten UK charities have each won £25,000 in recognition of their outstanding contribution to improving health care. The charities beat more than 400 entrants to become winners of this year’s GlaxoSmithKline (GSK) IMPACT Awards, run in partnership with The King’s Fund.
David Redfern appointed as new Chairman of ViiV Healthcare
GlaxoSmithKline (GSK), ViiV Healthcare, and Pfizer today announced the appointment of David Redfern as the new Chairman of the Board for ViiV Healthcare with effect from 1st April 2011, following the retirement of Julian Heslop. David will continue to serve as Chief Strategy Officer at GSK, which owns a majority share in ViiV Healthcare.
